Home / Transcripts / Metropolis Healthcare Limited (METROPOLIS) · November 6, 2025

Metropolis Healthcare Limited (METROPOLIS) Earnings Call Transcript

November 6, 2025

National Stock Exchange of India IN Health Care Health Care Providers and Services earnings 63 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, ladies and gentlemen, and welcome to Metropolis Healthcare Limited's Q2 and H1 FY2026 earnings conference call, brought to you by BNP Paribas. This call might include forward-looking statements regarding the company, and those are based on what the company believes, thinks, and expects as of today's date. Such statements are not a guarantee of how the company will perform in the future. They may carry risks and uncertainties that are hard to foresee. As a reminder, every participant line will be in listen-only mode, and you'll have a chance to ask questions once the presentation is over. If you require assistance at any point during the call, please signal an operator by pressing star, then zero on your touch-tone phone. Kindly note that this conference is being recorded. I'll now hand the conference over to Mr. Tasir Sheikh from BNP Paribas, India. Thank you, and over to you, Mr. Sheikh.

Tasir Sheikh analyst
#2

Hey there, thanks. Morning, everyone. Welcome to the Metropolis 2Q FY2026 earnings call. I'm Tasir Sheikh, the India analyst covering Pharma and Healthcare Service at BNP Paribas, and I'd like to thank Metropolis's management for letting us host this call. Joining us from the Metropolis team today are Ms. Ameera Shah, Chairman and Whole Time Director; Mr. Surendran, Managing Director; Mr. Sameer Patel, CFO; and Mr. Awadhoot Joshi, Chief Business Development Officer. At this point, I'll turn the call over to Ameera ma'am for her opening remarks. Over to you, ma'am.

Ameera Shah executive
#3

Thank you very much, and good morning to all of you, and thank you for being with us today for the Q2 and H1 FY 2026 earnings conference call. With me are Suren, our MD, Avadhut, the Chief Business Development Officer, Mohan, Sameer, and the rest of the team and SGA. Our investor presentation and the related documents have been posted on the exchange as well as on the company's website, and I hope all of you have had a chance to look through them. Let me start with a quick look at the wider healthcare landscape before we turn to updates on the company's performance. The Indian healthcare sector is going through significant transformation, fueled by growing health awareness, improved access, and an emphasis on affordability. Patients are becoming more proactive when it comes to preventive care and early diagnosis, which means more tests per patient. With a strong focus on quality, accuracy, and credible reports, consumers today favor organized, trusted diagnostic chains over small, unorganized local labs. The competitive environment has stayed stable, with no significant new entrants. We are seeing a natural consolidation in the market, where numerous smaller, unorganized labs are struggling to stay viable because of rising compliance, technology, and quality requirements. This trend is speeding up the move toward organized and trusted diagnostic players, and Metropolis is well-positioned in that regard, given its brand equity, clinician trust, and superior quality standards.

Ameera Shah executive
#4

When it comes to our quarterly performance, this is an exciting moment for Metropolis as we keep delivering strong, broad-based growth of 23% year-over-year, along with continued margin expansion. That steady trajectory underscores how solid our strategy is, how resilient our business model is, and how disciplined our teams across the country have been in executing. We had previously stressed automation and digitization as key strategic priorities, and I'm glad to report that we're making strong progress. Across the last few quarters, we've rolled out a number of digital initiatives, among them a new Consumer App, a partner app for our partners along with lead automation for them as well, plus middleware auto-authorization in our labs, which helps improve our TFT, meaning our turnaround time, an upgraded inventory management system that drives material efficiency, and AI call quality monitoring in our contact center to improve the customer experience. Taken together, these initiatives are not only reinforcing our operational backbone but also lifting customer experience, quality, consistency, and scalability, all of which matter greatly to sustaining our leadership position in the premium diagnostic segment. Where acquisitions are concerned, our focus during the year has been on stabilization, process integration, and synergy realization. It's only been a few months, but the priority has been to standardize operating procedures and drive cost efficiencies as per plan.

Ameera Shah executive
#5

I'm glad to report that we're completely on schedule when it comes to the synergy realization we expect and the related timelines. Integration work is moving along without friction, at both the technology and the people level. Teams have been brought together under one unified performance framework, and product portfolios are being aligned so that cross-selling opportunities get stronger and relevance in local markets improves. As we planned, the first year centers on integration and efficiency, whereas the second year will concentrate on scaling revenue growth on top of this solid foundation. For the current year, our clear focus at Metropolis continues to be margin expansion and operating levels, with several levers in play: tighter cost controls, a better test mix, automation benefits, and productivity gains. Importantly, we have no new acquisitions planned over the next six to nine months, since we believe the immediate opportunity lies in scaling the business organically and reinforcing the key strategic drivers already underway. Our genomics journey keeps making steady progress, with Core Diagnostics leveraged as our base platform. Integrating Core has strengthened our capabilities in high-end molecular diagnostics, oncology, and next-generation sequencing. Obviously, it has improved our front-end connection with oncologists. We are now broadening the test menu, deepening collaboration with clinicians, and building a stronger R&D-driven pipeline for test development.

Ameera Shah executive
#6

Our upcoming center of excellence in Delhi is going to act as a hub for innovation, training, and scientific excellence, which further strengthens our leadership in research-driven diagnostics. On the GLP-1 therapy side, we're keeping a close watch on how things develop as this drug class broadens its footprint in metabolic and weight management treatments. Such therapies require regular, repeat diagnostic monitoring so their efficacy and safety can be assessed. We see a long-term structural opportunity here to use our deep clinician network to co-create testing protocols, packages, and wellness, plus disease management pathways aligned with GLP-1-based treatments. Finally, the Metropolis moat keeps getting stronger. Our differentiators stay the same: an unwavering commitment to quality, wider accessibility, and a more customer-centric approach. Those core strengths have produced high customer and doctor retention, a top-ranking Net Promoter Score, and a steady rise in revenue per patient and revenue per test. Our focus has always been on the quality of business rather than just volume, making sure that every customer interaction builds trust, loyalty, and long-term customer value. In essence, we're building a resilient, future-ready diagnostics company, one that balances growth with profitability, science with empathy, and scale with precision. With that, I now hand the call over to Suren, who will take you through the company's strategic updates and operational performance for the quarter and half-year ended September 2025.

Ameera Shah executive
#7

Suren, the floor is yours.

Suren Chemmenkotil executive
#8

Thank you, Ameera, and good morning — a very warm welcome to everyone who has joined this call. We're happy to share that for quarter two and H1 of financial year 2026, group revenue rose 23% compared with the same period a year earlier. At Metropolis, organic revenues were up 12% in quarter two, and margins came in at 26.8% versus 26.2% in quarter two last year — a 60 basis point gain, consistent with the guidance we gave. Revenues for the True Health and specialty segments rose 21% and 15%, respectively, year-on-year on an organic basis. The group-level EBITDA margin stands at 25.4% in quarter two, with core diagnostic EBITDA improving as planned to high single digit, up from break-even in March. Last quarter, that figure was 23.1%. Turning to the second quarter, fever-related test volume did increase, though growth was slower than in a typical monsoon season and below expectations, mainly because common infections such as chikungunya, malaria, dengue, and viral fevers occurred less often. Even so, Metropolis stayed well-positioned by swiftly realigning where we focus and by stressing growth in specialty testing and True Health offerings. That proactive stance let us offset the drop in seasonal volumes, keep overall business momentum, and deliver revenue growth of 23% year-on-year.

Suren Chemmenkotil executive
#9

For the quarter, our B2C segment brought in 59% of total revenues and posted 11% year-on-year growth for the organic business. That double-digit increase came from strong results in our True Health and specialty segments, backed by targeted micro-marketing efforts and ongoing clinician engagement programs. Even with fewer fever-related cases, our Mumbai revenues rose 13% year-on-year in quarter two, which reaffirms the strong leadership we hold in the Mumbai market. The B2B segment represented 41% of total volumes and delivered 14% year-on-year growth for the organic business. Both higher patient volumes and improved realizations drove that growth. Our clinical trial business also made a strong contribution this quarter, which fits well with our specialty focus. With ongoing upgrades to our partner portals, better transparency, and more efficient service, we remain optimistic about achieving higher volumes in the quarters ahead. As Metropolis moves into its next phase of growth, improving productivity and operational efficiency will be essential to delivering sustainable progress. We are focused on maximizing output while upholding superior service quality through the core levers of driving people productivity, process, and lab operation efficiency via AI and digitization. This 6 to 12 month roadmap is built to lay the groundwork for scalable and profitable growth and to keep positioning the company for leadership in specialty.

Suren Chemmenkotil executive
#10

Under the Metropolis 3.0 strategy, our ongoing priorities are these: first, speeding up our footprint in new markets, concentrating on tier two and tier three cities. With our lab expansion program finished last year, we're now growing the collection center network that supplies those labs and lifts throughput. During H1 we added roughly 200 centers, and we intend to add another 300 in H2. As mentioned earlier, we now operate in 750 towns, and within those towns we're going deeper by bringing in new clients, connecting more clinicians, and raising consumer awareness of our brand. Second, we're reinforcing high-end specialized testing capabilities by improving AI-based allergy testing and AI-based diagnostics, expanding the genomic segment, and pursuing many other areas. Third, we're upgrading the True Health portfolio via science-led bundling, doctor consultation, and an integrated approach that includes basic radiology, which lets us serve the higher ends of the market along with lower rural packages for tier three and tier four towns. Fourth, we're integrating digital and AI-driven tools to improve service quality and operational efficiency, which supports sustainable growth and scalability. To conclude, I'd like to emphasize that our H1 performance has largely tracked our guidance, delivering organic revenue growth of 12 to 13% and margin expansion of approximately 40 basis points year on year thus far.

Suren Chemmenkotil executive
#11

We still feel confident about hitting the estimates we've stated for H2 this year. With these strategies in place, along with disciplined execution, a strong leadership team, and alignment around a common vision, we're confident in our ability to keep building and reinforcing our leadership position nationwide. With that, I'll hand things over to Sameer to walk you through the financial numbers for the quarter and H1. Thank you, and over to you, Sameer.

Sameer Patel executive
#12

Thanks, Suren, and good morning to all of you. I'd like to walk you through some of the key financial results for quarter two of FY 2026. As we communicated last quarter, we've split our performance reporting into two parts for this year. MHL Group takes in three acquisitions — Core Diagnostics, Dr. Ahuja's Pathology, Dehradun, and Scientific Pathology, Agra — while MHL Organic leaves those three acquisitions out. In addition, we've revised how we define the B2C and B2B segments to align them with industry standards. B2C covers all own franchising and rural centers, while B2B covers B2B lab, hospital, government, corporate, and clinical trials. Turning to the financial and operational performance, I'll begin by highlighting the operational results for MHL on an organic basis. Revenue and EBITDA each rose by 12% and 14.5%, respectively, while PAT was up 13.6% year on year. Patient volume came in at 3.6 million, up 6% year on year. Test volume reached 7.4 million, also up 6% year on year. Given the rising contribution from the True Health segment, we count one profile as one test, which differs from how peers do it. On a like-to-like basis with peers, that figure would be considerably higher. Our B2C revenue came in at INR 230 crore, up 11% year on year, and B2B revenue growth was 14%.

Sameer Patel executive
#13

The True Health and specialty segments expanded 21% and 15%, respectively. Under the revised B2C segment classification, B2C accounts for 59% of total revenue. Specialty B2C segment revenue was up 16%, while the B2C True Health segment rose 20% year-on-year. B2B revenue makes up 41% of total revenue, and B2B specialty posted 15% growth. MHL's organic EBITDA came in at INR 104.8 crore, up 14.5% year-on-year. The organic EBITDA margin for MHL was 26.8%, an improvement of 210 basis points sequentially and 60 basis points year-on-year. Organic PAT for MHL was INR 530 million crore, a rise of 13.6% year-on-year. MHL's organic PAT margin was 13.6%, up 20 basis points year-on-year. Turning to the key performance indicators for the MHL Group. Group revenue increased 22.7% year-on-year. Patient volume was 3.7 million and test volume was 7.9 million, growing 11% and 12%, respectively. B2C revenue rose 16% and B2B revenue rose 33% year-on-year. At the MHL Group level, the North region provides 19% of overall revenue, mostly due to recent acquisitions, which have their main presence and revenue generated in the North region.

Sameer Patel executive
#14

On a year-on-year basis, revenue growth was 26% from tier one towns and 13% from tier three towns. Tier three towns now account for 24% of total revenue. B2C revenue contributed 56% in Q2 FY26. The drop in B2C versus the 59% from the organic business is mainly because of the consolidation of Core Diagnostics, whose revenue mostly comes from B2B. EBITDA margin for the MHL Group was 25.4%. That decline was largely due to Core Diagnostics' lower margin profile. Still, we're pleased to report that Core's margin improved from low single digit to higher single digit in Q2 FY26 versus quarter one FY 2026. PAT for the MHL Group was INR 52.9 crore, a margin of 12.3%. That's all from my side. With that, I'll open the floor for questions and answers.

Operator operator
#15

Thanks a lot. At this point we'll open things up for questions. To ask one, just hit star and one on your touchtone phone. Should you want out of the queue, press star and two. We ask that everyone use their handsets when posing a question. Ladies and gentlemen, give us a moment while the queue fills up. Our first question comes from Anshul Agarwal at Emkay Global. Go right ahead.

Anshul Agarwal analyst
#16

Morning, everyone — thanks for having me. I hope you can hear me clearly.

Operator operator
#17

Yes, we can hear you. Go ahead, please.

Anshul Agarwal analyst
#18

Okay, first off, I want to ask about margins. How are we supposed to think about margins going forward? I mean, we've reported solid organic margin expansion. Should we be expecting that to keep going as core ramps up in the back half of the year, or are we staying with the margin guidance we gave before — roughly flat, since core is dilutive?

Operator operator
#19

Suren.

Suren Chemmenkotil executive
#20

Yes. As you’ll recall, at the start of the year when we gave the estimates, we said that for the full year, the organic business would deliver margins roughly 70 to 100 basis points better than the prior year, and the prior year was 24.3%. We said we’d improve by 70 to 100 basis points, and even now we remain committed to that same number. We said that for the group overall, there would be dilution of 1%-1.2% due to Core’s lower margins. By the time we exit this year, Core will be near two-digit margins. These are the statements, I mean, that we made at the beginning of the year, and all of them stay the same as of this point in time. We’re moving in that same direction.

Anshul Agarwal analyst
#21

Just a follow-up to get a clearer picture on this. Margins in our organic business have come in above what we would have expected at the start of the year. That was the angle the question came from.

Suren Chemmenkotil executive
#22

Right. So, Anshil, the second quarter tends to be a fairly high-volume one, which means your margins are certainly going to come in above the average for the year. So there's no reason quarter two margins have to hold at that same level as we move into quarter three and quarter four. On a full-year basis, starting from 24.3, you'd be looking at 70 to 100 basis points of upside by the time we finish out this year for the full year. That's the trajectory for the organic business.

Anshul Agarwal analyst
#23

Understood. Would that not depend on the mix of B2C and B2B for us, or would it?

Suren Chemmenkotil executive
#24

My sense is that the B2C/B2B mix will feel some effect, yet we don't foresee any major change in that split as we move ahead — right now it stands at 59% and 41%. It's possible the B2C share ends up somewhat higher by the time we close out this year.

Anshul Agarwal analyst
#25

Understood. The second question concerned True Health. During your opening comments, you noted that we're adding some radiology tests to the True Health packages. Would that kind of thing basically be confined to filling prescriptions, or at this point would we consider moving into advanced radiology?

Suren Chemmenkotil executive
#26

Right now, as far as radiology goes under True Health, the plan covers basic services such as the ECG, X-ray, and ultrasound. Those three are essentially what we're adding into the True Health packages, and we now have the ability to add the ECG nationwide, plus X-ray and ultrasound in roughly five towns across the country. These are now integrated into the True Health packages, and they're not high-end. For the remainder of this year, in this setup, we aren't including very high-end radiology such as MRI or a CT scan, and so on.

Anshul Agarwal analyst
#27

Understood. My final question concerned our guidance for volume or the top line. As I see it, pricing is stable in this environment, so to speak. Given additional tailwinds surrounding GLP-1 drugs along with specialized testing, would we more or less keep the top-line guidance we set out at the beginning of the year?

Suren Chemmenkotil executive
#28

Yes. As I said, we’ll stay with the top-line guidance for the remainder of the year too.

Anshul Agarwal analyst
#29

Alright, thanks. That's all I have.

Suren Chemmenkotil executive
#30

Much appreciated, Anshul.

Operator operator
#31

Thanks. Before we move to the next question, a quick reminder for everyone: you can press star and one to ask a question. Our next question comes from Sanjay Chakrabarty at BNP Paribas Securities India. Please go ahead.

Sanjay Chakrabarty analyst
#32

Morning, everyone, and thanks for having me. I'd like to start with a question about the lab testing charges. I realize this is a pretty minor item next to your other operating expenses, but when you look at it half-yearly, that cost has nearly doubled. I just want to get a sense of what's driving that, and whether we should expect that same quarterly run rate for this expense in Q3 and Q4 as well?

Suren Chemmenkotil executive
#33

Hold on just a second. You mean the charges for lab testing, correct?

Sanjay Chakrabarty analyst
#34

Correct, that's accurate.

Suren Chemmenkotil executive
#35

What was that? Hold on a moment. Yeah. I believe that for H1, 60% of lab testing charges stem from the core outsourcing charges paid to Core. Apart from that, nothing has really shifted in a significant way, and this is solely due to the Core integration, and those trends will stay the same through the remainder of the year.

Sanjay Chakrabarty analyst
#36

Thanks for that. My second question concerns the revenue you posted this quarter. Could you break out how much of the top line from the acquired assets was contributed by each one — for instance, how much revenue came from Core, from Dr. Ahuja, and from Scientific Pathology? That's possible.

Suren Chemmenkotil executive
#37

My sense is that, taken as a whole, 11% of the revenue growth has come from all of the integrated entities. Perhaps — I mean, we could discuss it afterward and provide the specifics on each of the entities that contributed to each one.

Sanjay Chakrabarty analyst
#38

That sounds fine. If I could just ask one more question. Turning back to margins. If I remember right, you previously guided to a high single-digit margin for core. Since you already delivered a high single-digit margin in the second quarter itself, do you still hold to that earlier guidance for core, or do you believe there's room for a low double-digit margin in FY 2026? What's your view on the margin? Yeah, please.

Ameera Shah executive
#39

Okay, no — for FY 2026, I think we're going to stay with high single-digit. Because, as you know, Q1 was, I believe, roughly a 2%-3% margin. Q2, as we mentioned, is kind of mid to high single digit. In Q3, we're hoping to get to a higher single digit, and then in Q4 get to something closer to a double digit. The average across the year will still land at a high single digit, which gives us a solid foundation to leap into next year and obviously get to a double-digit margin, on track with what we had kind of projected when we actually did the acquisition. I think the synergies are unfolding the way we expected, but typically with these acquisitions, what we've observed is that whenever you acquire one of these businesses, there's a certain amount of practice cleanup that needs to happen, changes in ways of working that need to happen, integration that needs to happen. In services businesses, this not only takes a bit of time, but it also means that sometimes you might discontinue certain businesses, and so on. Whatever cleanup is needed, we're doing it in year one on the revenue side, so that you don't carry that into the future.

Sanjay Chakrabarty analyst
#40

Thanks a lot. I’ll return to the queue.

Operator operator
#41

Appreciate it. For anyone on the line who’d like to pose a question, you can press star and one on your touchtone phone. Our next question comes from Shyam Srinivasan at Goldman Sachs. The floor is yours.

Shyam Srinivasan analyst
#42

Yes. Morning, and thanks for the question. So, Ameera and Suren, on how intense competition is right now — perhaps in B2B as well — could you share some qualitative observations? Your B2B revenue growth is beginning to look better now. I just want to get a handle on that. Does this reclassification affect any of those figures at all? It appears the B2C share has risen to 59%. On a like-for-like basis, I can see what you have shifted to in terms of definition, but where were our classifications previously, and does that materially affect your growth rates for these two segments?

Ameera Shah executive
#43

I'll take the first question, and Suren will handle the second one. On competitive intensity—obviously, during COVID, a lot of health tech players jumped in. A bunch of pharma companies came in, hospital players too. In the last couple of years, though, we really haven't seen new entrants come in any significant way. On the B2B side, some existing players are stepping up their efforts, but we haven't seen any escalation in price competition. We're actually seeing a fair amount of stability there over the last one or two years. It's still obviously an intensely competitive environment—it always has been, and that'll be true for many, many years to come. Nothing new or disruptive is really spoiling the market. Also, the fact that B2B growth was higher in Q2 isn't necessarily just about our execution improving—which it partly is—but it's also about the nature of the tests generated in the quarter. This quarter, we saw more specialty and more acute business in the market and less routine, which shows up as lower B2C growth because of the lesser routine, but higher specialty growth and higher B2B growth.

Ameera Shah executive
#44

Part of that comes down to product mix, and that's really specific to this quarter. And yes, our B2B execution keeps getting stronger as we move forward. Suren, would you like to take the question about the B2C contribution.

Suren Chemmenkotil executive
#45

Okay, so Shah, as you may recall, over the course of the past year, throughout all of those conversations, we said that we were simply eliminating a portion of the low-margin and troublesome B2B corporate government business, and so on — that cleanup was in fact completed last year, and we're now operating from a much cleaner base. That's the first point. The second point is that, following that, the institutional business has genuinely grown relatively much smaller. As a result, we now refer to the institutional business and B2B jointly as what was previously called B2B. The other shifts in the person are merely a mathematical rearrangement once that's done. Aside from that, at the base, nothing fundamentally was altered. In quarter two as well, in particular, I should mention that we secured one solid contract on clinical trial. That helped us bring our B2B above the usual run rate in quarter two. It was a project specific to that one quarter that we had.

Shyam Srinivasan analyst
#46

Understood, that’s useful. The second question concerns the GST impact. I’m aware that you gain certain advantages on the sourcing side. So I just want to clarify: are you quantifying that effect, or, as I suspect may be the case, do you have to pass it along? Specifically, how does it come through to you in the second half?

Suren Chemmenkotil executive
#47

Okay, so GST affects things in two ways. The first is on reagents and consumables, and the second is on equipment at the time we buy it. Now, on reagents and consumables, a portion of those items was already taxed at just 5% GST. Certain reagents and consumables have shifted from 12% down to 5% GST. It's not a particularly large benefit, so to speak, but any benefit we do receive, we intend to pass along to the customer in one way or another. Any GST benefit we realize from equipment purchases will actually fall under procurement efficiencies.

Shyam Srinivasan analyst
#48

That's useful — thanks, and best of luck.

Suren Chemmenkotil executive
#49

I appreciate that.

Operator operator
#50

Much appreciated. At this point, everyone, if you'd like to pose a question, hit star and one. Our following questioner is Raman Kavi, calling in from Sequin Investments. The floor is yours.

Raman Kavi analyst
#51

Hi there. Is my audio coming through?

Suren Chemmenkotil executive
#52

Yes.

Raman Kavi analyst
#53

What revenue did the radiology segment generate in the quarter and in the first half?

Suren Chemmenkotil executive
#54

Our radiology segment is extremely tiny — extremely tiny. We're at an early stage with radiology; it's a very, very small piece. If you ask me, it's a very low single-digit percentage.

Raman Kavi analyst
#55

Right. Essentially, it isn't making a meaningful contribution to your total.

Suren Chemmenkotil executive
#56

No. At this point, no.

Raman Kavi analyst
#57

When it comes to True Health and Core Diagnostics, what's your strategy for growing revenue in the radiology segment? Do you have any plans for that?

Suren Chemmenkotil executive
#58

Core Diagnostics — radiology isn't reflected there at all. It's just our own work, nothing else. Let me share a few details with you. Across the country we now have roughly 35 centers, and all of them are fully outfitted with the core radiology testing capabilities — X-ray, ultrasound, 2D echo, and ECG, and so on. So that's 35 centers spread over about five cities, all now fully equipped, and we'll begin pushing radiology at those centers, plus bring the True Health portfolios, radiology included, into those five cities. That's one opportunity we can use to move things forward. The second piece is ECG capabilities, which we've now nearly completed nationwide. That will begin to pay off as well. Those are the two opportunities, at least for the remainder of the year. Those are the two levers we have in the radiology segment, and from here we'll start making this portfolio stronger as we go.

Raman Kavi analyst
#59

Got it. On my second question, that's about the clinical trial. Could you walk through the business side of it and share how you're seeing traction there? What share of overall pathology volumes and revenue does it account for today?

Suren Chemmenkotil executive
#60

Clinical trial work, I'd say, makes up a pretty tiny slice of the business. There was just one contract in quarter two, and we delivered it during quarter two. Essentially, it involves partnering with pharma companies and other alliances on certain turnkey projects. It isn't something we hold onto — I mean, not on a constant basis, since it depends — but it's a fairly minor portion of the business.

Raman Kavi analyst
#61

How do the margins in this business look? Are they above the consolidated margins, or below them?

Suren Chemmenkotil executive
#62

Yes. That's slightly above the margins we see at the company level.

Raman Kavi analyst
#63

Do we intend to take on additional turnkey projects — those kinds of turnkey clinical trial projects — or are you instead attempting to become consolidated?

Suren Chemmenkotil executive
#64

We're among the main participants in this segment. The market itself isn't especially large here, yet we're a significant player in it, and a few other small operators exist too. We genuinely pursue every opportunity that's out there, and then we continue seizing these sorts of opportunities whenever they arise.

Raman Kavi analyst
#65

My last question concerns Core Diagnostics. You said on this call that by the end of this year it will head toward double digits. By the first half of FY2027, could we expect Core Diagnostics margins to reach a level comparable to Metropolis?

Suren Chemmenkotil executive
#66

No, no. During the first half of the year, we stated it's a single-digit figure. As we exit this year, we'll get nearer to a double-digit figure. For the full year, we'll remain at a really robust single-digit figure. We stated that across a three-year span, we'll raise this to the margins Metropolis currently has. Getting up to Metropolis margin levels will require another 2 to 2.5 years beyond that. The work is underway, and we're heading the right way.

Raman Kavi analyst
#67

Oh, okay. So what you're saying is, by FY 2028, it'll get to roughly a 23%-24% margin — is that about right?

Suren Chemmenkotil executive
#68

This is our third year — yes, the third year since the acquisition.

Raman Kavi analyst
#69

Turning to volume, are we keeping up — you posted solid revenue and volume gains in the first half. Do we intend to hold that mid-double-digit volume growth across the full year, or are you looking for — do you expect considerably better than that?

Suren Chemmenkotil executive
#70

At the consolidated level, we expect volume growth to stay in double digits—10%-11%—for the remainder of the year as well.

Raman Kavi analyst
#71

Alright, thank you, sir.

Suren Chemmenkotil executive
#72

Appreciate it.

Operator operator
#73

Thanks. We’ll take the next question from Ankeet Pandya at Baroda BNP Paribas Mutual Fund. Go ahead, please.

Ankeet Pandya analyst
#74

Yeah. Hi. Good morning, and thanks for the chance to ask. I have 2 questions. First, we finished our big lab expansion last year, and this year we're putting money into collection centers. From FY 2027, FY 2028 onward, could we see growth numbers rise from the current 11%-12% to roughly mid-teens over the next 1 to 2 years?

Suren Chemmenkotil executive
#75

For me to provide a projection for the coming year, it's a bit too soon. Give me a couple more quarters so I can give you the right projection for the coming year. The effort is always to take the growth level to the next level as we move forward.

Ankeet Pandya analyst
#76

All right, thanks. And finally, regarding the GLP, I realize it's obviously too soon for any guidance or figures. But have you noticed any pickup when it comes to more testing around obesity or weight management over the past 1 to 2 quarters, since one molecule is already on the market? Has testing gone up at all in that area?

Suren Chemmenkotil executive
#77

Right now, there isn't anything really notable on the growth front as such, but we're quite hopeful this will be of help to diagnostic operators in the days ahead. I mean, full-fledged availability of this medicine and its usage in India has still not taken place. As per our information, I think it may occur sooner rather than later. Once they begin using it, then diagnostic testing will keep happening so reports can be obtained in between while they are taking the medicine. I mean, we're hopeful this will assist us in the coming quarters.

Ankeet Pandya analyst
#78

Alright. Alright. That's all from me. Thanks.

Operator operator
#79

Thanks. Our next question comes from Surya Patra at PhilipCapital India Private Limited. Please go ahead.

Surya Patra analyst
#80

Appreciate the chance to ask. My first question concerns the Core Diagnostics integration—is that integration completely finished at this point? Tied to that, here's what I'm seeing: for the last two quarters, we've been seeing revenue per patient grow at a strong double-digit rate. Is any of that positive movement in this number coming from Core Diagnostics?

Suren Chemmenkotil executive
#81

Yeah, so I apologize for that.

Ameera Shah executive
#82

Yeah.

Suren Chemmenkotil executive
#83

All right, I'll go ahead and start.

Ameera Shah executive
#84

Let me just add a point here, and Suren, feel free to build on it. Look, whenever you make an acquisition, what we tend to find — as I said earlier — is that in India, different organizations follow all sorts of practices. Historically, what we've observed is that each time we complete an acquisition, we genuinely need to devote the first several months to tidying up certain legacy practices that might not fit cohesively as Metropolis moves forward. That typically causes a short-term dip in the acquired entity's revenue. For any business we've already halted and are in the process of cleaning up, revenue growth during the first six months of the year would have been negatively affected at the core. Once that cleanup is complete, it lays the groundwork for quicker growth down the road. Hopefully we'll see that unfold. That will clearly have an impact on overall MHL growth too. On the second part of your question — whether integration is finished — look, in services businesses, what you're integrating is mostly people and cultures, alongside technology and processes. The technology, processes and infrastructure piece is somewhat simpler to handle. The people and culture piece clearly takes longer than six months.

Ameera Shah executive
#85

That’s going to keep being something we work through as the policies, guidelines, and ways of working get integrated. Culture and a few of those areas are going to take somewhat more time to finish. We’ve already—and maybe Avadhut and Suren can speak to this—we’ve already done some of it. The replication and infrastructure have already been taken out. Anywhere we had duplicate infrastructure, it’s been shut down, and anywhere we could capture synergies from procurement or corporate cost, that’s been completed. Obviously, there are some new costs that have come in, such as technology, audit, and other items that they may or may not have been handling the same way we’re choosing to handle them today. Suren and Avadhut, if you’d like to add anything.

Suren Chemmenkotil executive
#86

No, I believe that point came from you. You raised the question about whether the integration has finished. No, it's still a work in progress. My sense is that it will probably take a couple more quarters before the full integration is done. Yes, on patient volume growth, there is certainly some effect from Core Diagnostics volumes as well, which are helping us with overall patient volume growth for the company.

Avadhut Joshi unknown
#87

That sounds good. On the second point, a related aspect: see, thanks to the Core integration, the quality and capability of the service offering would now obviously have seen some kind of improvement. Because of that, have we seen any upgrade to our True Health portfolio package, and also, recently, what we have added, the ECG, to this thing, True Health? Have these two — the Core integration as well as the ECG — whether that has created any uptick in the average realization for your True Health packages?

Ameera Shah executive
#88

Okay, just to clarify: we acquired Core Diagnostics because it’s a genomics-based platform focused specifically on oncology. So the customers you’re selling to are mostly oncologists, as well as oncologists based inside hospitals, right? Now, as we keep expanding our genomics portfolio beyond oncology—into neurology and, obviously, into women and child, etc., which we’re already doing—this will obviously bring in all of these other customers. This won’t affect your True Health profiles, because your True Health packages are largely more routine tests—things where consumers decide to come in and sort of do a bundle of a checkup every year. Some people talk about using genomic tests for packages like this, which can give you a predictive or preventive outlook. Just to clarify on that: those things are not yet scientifically proven. Doing it on a preventive basis—doing a genetic test on a preventive basis—the data doesn’t exist for India today that lets you make a good, correct scientific decision based on that. We do not offer genomic tests as part of a preventive profile at this point in time.

Ameera Shah executive
#89

The True Health packages won't be impacted by this. With the True Health packages, RPP is rising since we can offer patients a greater number of scientifically relevant tests suited to them. For these packages, patients are ready to pay a higher price to us—for the brand, the premium, the quality of care, and the accuracy we deliver, perhaps relative to others.

Avadhut Joshi unknown
#90

Yes. Thank you, ma'am. My following question concerned the AI benefits. Look, clearly this remains theoretical up to now — that, okay, AI initiatives are helping us. Have you observed any tangible benefit as of yet? Could you put it another way — that, okay, what sort of investment goes into the AI-related side, or the upgrades? What tangible benefit have you either begun to see or expect to see moving forward? In what shape will you be seeing the real benefit here?

Ameera Shah executive
#91

Look, to speak about AI specifically, I mean, people discuss it in two distinct categories, correct? The first concerns productivity and efficiency, in which you can substitute manual labor. On the non-medical side, you can make processes smarter and thus have a more productive workforce, right? The second involves applying AI to medical tests where doctors and all of that aren't needed. I want to keep these two apart. Regarding AI on the non-medical side, I believe there are genuine use cases. Organizations in various industries are deploying AI, say, for recruitment, screening profiles, talent onboarding, billing, all sorts of things, accounting. I think those are real-life use cases spanning industries. I think those are quite feasible and can be implemented to derive tangible benefit. We're early in that journey, but there are several things we're attempting to put in place that should hopefully get us there over the next year or so. That will clearly be an ongoing journey, a work in progress. We're putting resources and time into that area.

Ameera Shah executive
#92

The second piece of AI — applying it to medical tests without doctors — is a highly hypothetical situation. As we see it, AI serves as an instrument that helps physicians reach improved decisions rather than something that takes their place. So once more, this comes down to productivity inside the physician space. At present, with AI, the software or tools you receive come from the U.S. or Europe, and those cannot be plugged and played directly into the Indian ecosystem, since you require Indian data sets to make such AI models pertinent for the Indian patient — and at this point, that simply does not exist yet. I believe this remains very much a work in progress across the entire industry. Several years will be needed before those become relevant for the market here from a medical standpoint. You are seeing AI applied to large-scale screening. Take, for instance, TB diagnostics, which the state of Maharashtra is carrying out with AI, where chest X-rays are being used with AI, and so on. That is not a confirmatory diagnosis. It is very much a screening tool. The precision today is not there to deliver a 100% accurate report from it as yet. I hope that answers your question.

Surya Patra analyst
#93

Yes, yes. Truly, ma'am. Allow me just one final point. Now, clearly, you're observing the sweating of assets following the creation of substantial network expansion. At the same time, during this process, you're discussing expanding the pickup points of the collection centers. Is there some kind of standard equation that you believe you'll reach at that level when it comes to adding collection centers, given your network expansion? Is there any equation between a collection center and a lab, or a collection center and, say, your patient service center — such an equation that you have in mind? I think neither within the company nor within the industry is there any such ratio of lab versus collection center as such. We currently sit at roughly 20 to 22 centers per lab that we have, if I look across the country. The first destination is that we would like to take this to 30 centers per lab. That may happen perhaps within the next 12 to 18 months' time. That is the first destination. We will look at lab profitability, and lab profitability has to begin getting better. That is one aspect. The second aspect is that most of the service center additions we are talking about come through the franchisee route.

Surya Patra analyst
#94

Only a handful of these will operate via our own centers, and just in the top five or six cities. We'll be adding our own collection center. Everything else is going to run through franchisees. So there won't be much of an impact on the company's overall profitability. As we grow the collection centers. Sure. Thanks a lot for all of this.

Suren Chemmenkotil executive
#95

I appreciate that.

Operator operator
#96

Thanks. Our following question comes from Aashita Jain with Nuvama. You have the floor.

Aashita Jain analyst
#97

Hello there. Good day to all of you. I have just a couple of questions. First, regarding that 12% organic growth, what share would you say came from the price increases we implemented last year? And are there any plans to raise prices again in the year ahead?

Suren Chemmenkotil executive
#98

All right. I'd say about 2% of that growth has to be put down to the price increase. And we definitely aren't planning any further price rises over the course of this financial year.

Aashita Jain analyst
#99

OK, so second, regarding Core Diagnostics — we did say we're doing some cleanup there, and with the other acquisitions too. How should we think about Core Diagnostics revenue for this year? And how should we look at Core Diagnostics along with the three other acquisitions — how those portfolios will grow over the coming years? Would that growth outpace our standalone growth rate?

Suren Chemmenkotil executive
#100

I believe Ameera made that clear to you, actually, in response to one of the questions asked earlier regarding overall growth, since right now we're simply cleaning up the business. We aren't really focusing on year one in terms of revenue growth so much. What we're doing is making certain the entire portfolio is very sound, clean, and stronger. That's the focus for year one. In year two, naturally, we'll be pursuing revenue growth across all of these acquired entities. That should certainly give the group's overall growth a further boost in the years ahead.

Aashita Jain analyst
#101

Got it. Is it possible for these to expand at a quicker pace than our organic growth?

Suren Chemmenkotil executive
#102

I'd say give us a couple more quarters before we can answer that more specifically. I think we'll work out the estimate as we get nearer to the close of this year.

Aashita Jain analyst
#103

Okay, and one final quick item from me. Looking at the below-EBITDA line items this quarter, depreciation came in higher while other income was lower. Is there anything we should read into that?

Suren Chemmenkotil executive
#104

Yes. Give me a second. Maybe one or two.

Avadhut Joshi unknown
#105

The decline in other income comes down to the fact that we had cash last year, and we used it in March to acquire Core. That's why investment income is lower. That's what's driving the drop in other income. As for depreciation, we certainly added assets during last year, and now the annualized effect of that depreciation is showing up. Overall, that's where it has gone.

Aashita Jain analyst
#106

Absolutely. Thanks. That's everything from me.

Operator operator
#107

Thanks. We’ll take the next question from Yogesh Soni at InCred Capital. Your line is open.

Yogesh Soni analyst
#108

Yeah. Hi there. Thanks for giving me the chance. Most of the questions have already been covered. There's one thing I'd like to get a handle on, and that's on the test volume side. If someone wants to break down industry volumes into doctor consultation tests, the routine monthly tests that patients get done, and emergency tests, could you help me understand, I mean, what sort of contribution each of those would make on the overall volume side? If not for Metropolis, then broadly for the industry?

Suren Chemmenkotil executive
#109

I'm not really great with those figures. We might need to get in touch another time so we can at least provide the most accurate answers for you.

Yogesh Soni analyst
#110

Alright, I just want to get a sense of the Core Diagnostics scale-up you brought up near the beginning of the call for FY 2027 — once the integration wraps up and we've captured those initial synergies in FY 2026, what type of growth should we be expecting for Core?

Suren Chemmenkotil executive
#111

That is precisely the point I believed I had already made clear when responding to the earlier question too. Once this year wraps up, we'll be in a position to begin providing you with accurate projections for each of the entities and the amount by which they will grow. I believe I mentioned that, taken as a whole, this ought to contribute to a further lift in the company's growth. That's the thing we will be focused on.

Yogesh Soni analyst
#112

Alright, thanks.

Operator operator
#113

Thanks. Our next question comes from Pranaya Jain at Bengal Pre-Advisors Private Limited. The line is yours — please go ahead.

Pranaya Jain analyst
#114

Hello, and good morning. Thanks for giving me this chance. There are two things I'd like to ask. First, could you discuss the consolidation taking place across the industry? Over the past 1 to 1.5 years, has that consolidation pace accelerated? Could you give us some color on it by geography — for instance, is the West consolidating more quickly than some of the other geographies? That's my first question. My second question concerns your clinical trial business — could you shed a bit more light on it? We're hoping to understand who your customers are and what types of projects these are. Any color on the clinical trial business would be very helpful. Thank you.

Ameera Shah executive
#115

Okay, I'll begin with the industry and with what we call consolidation. You know, the best and worst thing about our industry has been the low entry barrier—that's the reason you had many small companies, and we also watched many new, bigger companies come in. After people spend 2 or 3 years in this industry, they come to understand that although getting in is easy, scaling up is not so easy. In fact, it's difficult. And scaling up while making a profit is extremely hard. So after a few years, those who came in fast sometimes end up losing interest in the business, since they feel that, okay, either this will take extremely long, or making money from it won't be so easy. So then people ease off. Their aggressiveness in the market declines. A few of them close down, and a few simply remain there but are not very aggressive and active. Meanwhile, over the last 5 years, you've seen 3 shifts. First, there's been strong technology adoption in healthcare, which naturally means the more organized companies do better, since they have greater capability and capital for technology.

Ameera Shah executive
#116

Second, what you're seeing is consumers starting to pick brands because roughly 2,000 players gained more brand visibility during COVID, since those were the ones performing COVID testing, as opposed to the 300,000 players in India. So what you're seeing now is consumers preferring brands even in healthcare and in diagnostics. That makes it harder for the small single lab owners who are non-branded and don't have chains. I think a combination of these trends is leading to the organized sector growing a little faster and the small independent labs actually struggling to sort of make ends meet. Now, even among the independent labs, there are two varieties. You have the technician labs and you have the pathologist-run labs. The pathologist-run labs, which tend to be of better quality, are still doing fine, are able to survive. The challenge they're having is more in a succession plan because often their kids don't want to pick up medicine or pathology, and therefore some of them end up shutting their labs when they get older. The technician labs, which are the very subscale labs that don't really have a moat or don't really have a differentiator, are the ones really struggling and actually shutting down.

Ameera Shah executive
#117

On this, third-party data basically isn’t available in the industry. So anything we can share comes more from a sense of how the industry is behaving and what we’ve observed. We really don’t have data that lets us tell you whether it is specifically adding in more markets. My own belief is that markets that are more educated and aware — which is more the West and South — will probably see more consolidation, in my view, than markets in the North and East, where education is lower and so the emphasis on quality is lower. Also, in markets with little access, such as UP, Bihar, and other markets, you may still see labs mushrooming, whereas in the bigger cities it is harder to survive financially, given higher competition now and compliances. So the smaller labs will probably have a harder time. I hope that gives you enough insight into that area.

Pranaya Jain analyst
#118

Yeah, that was really useful. Could you also shed some light on my second question too?

Ameera Shah executive
#119

Clinical trials—yes, that's the area where we collaborate extensively with pharmaceutical firms. When a pharma company aims to bring a medication into India—whether it's an existing product or a brand-new one—they must conduct clinical trial studies prior to exposing it to humans and selling it commercially. You have phases I through IV. Our involvement is typically in phase II, phase III, and phase IV. We partner with these companies by handling all the testing for their clinical trials. They prefer to team up with organizations capable of collecting samples from sites throughout India, capable of sustaining the elevated quality standards they require, and capable of keeping all the documentation and audit trails necessary for securing approval from Indian FDA or US FDA. This line of business tends to be more structured and harder to break into, relative to the ordinary lab business. That's the reason only a handful of us in the market can actually deliver what we deliver. I might be mistaken, but my belief is that we're likely the biggest player in testing and clinical trials, or the second-largest is Avadhut Joshi.

Ameera Shah executive
#120

I didn't have anything further to add there. It's not a particularly big market, yet it is a reasonably profitable one, and it's a market where we've built a brand.

Avadhut Joshi unknown
#121

Yes. I believe that applies to what's happening with clinical trials, the bigger clients of drugmakers, and healthcare research organizations. As for the particular question you raised.

Pranaya Jain analyst
#122

This is only going to be for domestic testing, correct?

Suren Chemmenkotil executive
#123

Not always.

Ameera Shah executive
#124

The customer base is going to include MNC pharma companies along with Indian pharma companies as well. It will also include, in a sense, CROs that operate globally or in India, and those would be our customers too.

Pranaya Jain analyst
#125

Could we just clarify the size of this business for us?

Ameera Shah executive
#126

Actually, we don’t break that out separately right now. As I mentioned, this isn’t a particularly big market. It’s a market that’s expanding. Each year looks different since it hinges on how quickly drug approvals arrive. In some years it’s low, in others it’s high. Even though we invest effort there, we don’t anticipate it turning into an extremely large business.

Pranaya Jain analyst
#127

Got it. It won’t be dilutive to ROE, correct?

Ameera Shah executive
#128

Not in the slightest.

Pranaya Jain analyst
#129

All right, thanks.

Operator operator
#130

Thanks. Our next question comes from Aditya Chera at InCred Asset Management. The line is yours — go ahead.

Aditya Chera analyst
#131

Yeah. Hi. Morning. My question concerns the center expansion. In particular, across the past 3 years, growth in owned service networks/centers has moved faster — nearly doubled — compared with franchisee growth. Is that because of the North market, where more owned centers need to be opened, or could you explain the sale dynamics? Since you classify rural separately, would those be a mix of franchisee and owned? The last question is whether you can quantify, in number, the lab network and center network expansion you would be doing for FY 2026. Yeah. Those are the questions.

Suren Chemmenkotil executive
#132

I think if you look at the number, say two years ago, the owned network figures were comparatively lower. That's the reason why over the last two, three years, you're seeing a greater number of owned centers being added. Most of the labs also come together with the owned center. Over the past three years, we've added more than 100 labs. Each time a new lab is added, one additional center is also added. So that's how, across all the key cities, you'll see the owned network has genuinely increased. The franchisee network is otherwise largely how we'll grow the collection centers going forward. In rural areas, there are definitely no owned centers. As I said earlier, only the top five cities or six cities will have our own centers. Everything else will be franchisee centers. As I mentioned, for the remainder of the year, we estimate another 300 centers will come up.

Anshul Agarwal analyst
#133

Alright, that's all I've got. Thanks.

Suren Chemmenkotil executive
#134

Thanks.

Operator operator
#135

Thanks. Women and gentlemen, because of a time constraint, that was the final question for today. I'll now pass the conference to management for closing remarks.

Ameera Shah executive
#136

Thanks so much, everyone, for being with us today on the Q2 call. Our excitement and optimism about where our growth is heading remain very strong. It has been a substantial year for us: organic growth has performed well, and on top of that we completed these three or four acquisitions during the first half of this year. That is quite a lot to absorb, but we're glad to report that we're on track, and the team keeps pushing forward, delivering results both on the acquisition side and on the organic side. We expect the second half of the year to stay quite stable. Our energies will stay focused on really lifting productivity and on boosting and speeding up organic growth over the next six to nine months. Obviously, by March, April, when we return to you following Q4, we'll be very glad to share our thinking and plans for the coming year and the direction we believe we'll take. We believe this is a very positive period at Metropolis, and we're very excited about this year and the years ahead. I look forward to talking with you all further at the close of Q3.

Ameera Shah executive
#137

The third quarter is, of course, not always the strongest one of the year. Festivals usually make it the weakest. Even so, we keep giving our best efforts to accomplish as much as possible. Thank you, everyone.

Operator operator
#138

Thank you so much, ma'am. That brings this conference to a close on behalf of Metropolis Healthcare Limited. We appreciate your participation, and you can disconnect your lines at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Metropolis Healthcare Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Metropolis Healthcare Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.